SUTRO BIOPHARMA INC
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
STRO$10.61+10.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
(in thousands, except share and per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue | $153,731 | $67,772 | $61,880 |
| Operating expenses | |||
| Research and development | 180,425 | 137,171 | 104,400 |
| General and administrative | 62,584 | 59,544 | 56,004 |
| Total operating expenses | 243,009 | 196,715 | 160,404 |
| Loss from operations | (89,278) | (128,943) | (98,524) |
| Interest income | 14,510 | 3,455 | 577 |
| Unrealized gain (loss) on equity securities | 9,917 | 12,130 | (4,454) |
| Non-cash interest expense related to the sale of future royalties | (12,570) | - | - |
| Interest and other income (expense), net | (11,180) | (3,346) | (3,137) |
| Loss before provision for income taxes | (88,601) | (116,704) | (105,538) |
| Provision for income taxes | 18,192 | 2,500 | - |
| Net loss | $(106,793) | $(119,204) | $(105,538) |
| Net loss per share, basic and diluted | $(1.78) | $(2.35) | $(2.29) |
| Weighted-average shares used in computing basic and diluted net loss per share | 60,163,542 | 50,739,185 | 46,119,089 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.